Skip to content

Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers

Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01691105
Enrollment
1044
Registered
2012-09-24
Start date
2013-08-31
Completion date
2016-09-30
Last updated
2021-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking, Smoking Cessation, Tobacco Use Cessation, Tobacco Use Disorder

Keywords

Tobacco Use Cessation, Smoking Cessation, Nicotine Replacement Therapy, Hospitalized Smokers

Brief summary

This study will implement and test the effectiveness and cost-effectiveness of a tobacco cessation intervention (Academic Detailing + Integrated Tobacco Order Set - AD + ITOS) for adults admitted to the hospital. The intervention will begin during the hospital stay and continue after discharge. The intervention will use resources easily available to most acute care hospitals: computerized physician order entry, physician and nurse education, staff meetings for physicians, nurses and allied health professionals, online learning capabilities, faxing to primary care providers (PCPs), and the telephone counseling and support available from a state smokers' quitline (QL). The investigators hypothesize that the subjects in the intervention arm (AD + ITOS) will be more likely to achieve tobacco abstinence at 12 months post hospital stay than subjects in the control arm (Academic Detailing - AD). Tobacco abstinence will be assessed by self report and biochemical verification (exhaled carbon monoxide reading).

Detailed description

Cigarette smoking remains the leading cause of preventable death and illness in the United States. In 2008, 20.6% of all American adults smoked, and 435,000 died from smoking-related illnesses. Economic costs of smoking dependence are estimated at $193 billion/year and have far-reaching implications for the individual, workplace, society and the healthcare system. However, treatment is associated with significant individual and society benefits, and both counseling and pharmacotherapy have been demonstrated to be effective treatments. Along with poverty and low education, smoking causes a greater loss of quality-adjusted life years than race, uninsurance, overweight, or binge drinking. Smokers are admitted to acute care hospital more than nonsmokers. Using estimates from a number of sources, we estimate that approximately 6.1-12.5 million hospitalizations occur annually among adult smokers. This represents 20-41% of the 29.8 million annual inpatient stays in US acute care hospitals among adults age 18 and older unrelated to pregnancy or childbirth. Put another way, the nation's 46 million smokers represent 20% of the adult population, but account for 20-40% of all hospitalizations unrelated to pregnancy. Given that US hospitals are now smoke-free (per Joint Commission regulations), and many of these admissions are for tobacco-related conditions, the hospital admission represents a profound opportunity-a teachable moment-for tobacco control. Recent core measure regulations by the Joint Commission and the Centers for Medicare and Medicaid Services require hospitals to report publicly their tobacco screening for patients admitted with acute myocardial infarction, congestive heart failure, and pneumonia. Although many hospitals have improved their performance considerably on these smoking measures, sometimes this has resulted from gaming, e.g. giving all discharged patients a preprinted instruction sheet that includes boilerplate text about smoking cessation. Thus, although most hospitals assess inpatients for tobacco use (either through a nursing assessment or the physician's initial history and physical examination), there are often no systems in place to initiate or sustain tobacco treatment for smokers. This gap in service delivery prevents millions of smokers from accessing the many effective, evidence-based treatments for tobacco dependence during a period in which they may be particularly receptive to an intervention. Hence, the overarching goal of this project is to implement and study the effectiveness and cost-effectiveness of a tobacco intervention for hospitalized adults that begins during inpatient treatment and continues after discharge. To enhance dissemination, we will use resources currently available to most acute care hospitals: computerized physician order entry, physician and nurse education, staff meetings for physicians, nurses, and allied health professionals, online learning capabilities, faxing to primary care providers (PCPs), and the telephone counseling and support available from a state smokers' quitline (QL). In the final year, a toolkit will be disseminated by professional societies. We hypothesize that the proposed intervention is clinically effective, cost effective, sustainable, and generalizable. All interventions are evidence-based and consistent with the 2008 Public Health Service clinical practice guideline for tobacco dependence treatment. The Specific Aims of the proposed project are to: Primary Aims: 1. Determine whether Academic Detailing (AD) and an Integrated Tobacco Order Set (ITOS) compared to AD alone improves biologically verified smoking cessation at 12 months post-quit in a cohort of 960 smokers age \> 18 years admitted to Yale New Haven Hospital (YNHH). Secondary Aims: 2. Study ITOS's ability to encourage smokers to use treatment services and reduce consumption. 3. Study ITOS's ability to enhance provider delivery of tobacco screening and treatment. 4. Conduct an incremental cost-effectiveness analysis of the intervention. Our associated hypotheses are: 1. Subjects treated by physicians in the AD+ITOS arm will have a higher rate of biochemically verified 7-day point prevalence smoking abstinence at 12 months post-quit than subjects treated by physicians in the AD arm, in a cohort of adult smokers admitted to the inpatient units of Yale-New Haven Hospital. 2. Subjects treated by AD+ITOS physicians will have made more quit attempts, and experienced greater reduction in daily cigarette consumption, than smokers treated by AD physicians. 3. A higher proportion of patients treated by AD+ITOS physicians will have tobacco treatment initiated in hospital than patients treated by AD physicians. 4. Societal costs of AD+ITOS, per abstinent smoker, will be cost-effective relative to AD.

Interventions

OTHERAD + Integrated Tobacco Order Set

Physician will have access to: NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
National Institutes of Health (NIH)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * admitted to any medical ward, telemetry or cardiac care unit * identified as a smoker by the nurse or physician in the admitting EMR * treated by a study physician * able to give written informed consent

Exclusion criteria

* inability to read or understand English or Spanish * lacks capacity to give informed consent * currently receiving formal tobacco dependence treatment * current suicide or homicide risk * current psychotic disorder or life-threatening or unstable medical or psychiatric condition within past 6 months * unable to provide 2 telephone contact numbers * unwilling to follow up per study protocol, including release of information to assess treatment engagement at 30-days * live outside of New Haven County * leaving the hospital against medical advice * history of clinically significant allergic reaction to nicotine replacement therapies, varenicline or bupropion * use of an investigational drug within 30 days * use of tobacco products other than cigarettes * women of childbearing potential who are pregnant, nursing, or sexually active and not practicing effective contraception (oral injectable, or implantable contraceptives, intrauterine device, or barrier method with spermicide) * do not have access to a phone with a CT area code (required to use the CT Tobacco Quitline)

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Exhaled Carbon Monoxide Confirmed Abstinence12 months post enrollmentTobacco abstinence will be assessed by obtaining an exhaled carbon monoxide reading for all subjects self-reporting tobacco abstinence at 12 month follow-up. Consistent with manufacturer's recommendations, a cutoff of 10 ppm will indicate current smoking.

Secondary

MeasureTime frameDescription
Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 6 Months6 months post enrollmentSelf-report questionnaires are completed over the phone to assess reduction in cigarette use or abstinence from cigarette use. The Time Line Follow Back technique will be used to assess 7-day point prevalence abstinence.
Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 1 Month1 month post enrollmentSelf-report questionnaires are completed over the phone to assess reduction in cigarette use or abstinence from cigarette use. The Time Line Follow Back technique will be used to assess 7-day point prevalence abstinence.
Number of Participants Self-Reporting Use of Cessation Medications - 1 Month1 month post enrollmentNicotine replacement therapy (NRT) use and use of other pharmacotherapies will be assessed by self-report. A Treatment Services Review (TSR) will be administered during follow-up assessments at 1, 6, and 12 months post enrollment.
Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 12 Months12 months post enrollmentSelf-report questionnaires are completed over the phone to assess reduction in cigarette use or abstinence from cigarette use. The Time Line Follow Back technique will be used to assess 7-day point prevalence abstinence.
Number of Participants Self-Reporting Use of Cessation Medications - 12 Months12 months post enrollmentNRT use and use of other pharmacotherapies will be assessed by self-report. A Treatment Services Review (TSR) will be administered during follow-up assessments at 1, 6, and 12 months post enrollment.
Number of Participants Self-Reporting Treatment Engagement - 1 Month1 month post enrollmentTreatment engagement will be assessed by subject self-report during the 1 month follow-up interview. Subjects will be considered engaged in treatment if at 30 days after randomization the subject reports currently receiving care for the Quitline or another treatment program that addresses the subject's nicotine dependence.
Number of Participants Self-Reporting Use of Cessation Medications - 6 Months6 months post enrollmentNRT use and use of other pharmacotherapies will be assessed by self-report. A Treatment Services Review (TSR) will be administered during follow-up assessments at 6 months post enrollment.

Countries

United States

Participant flow

Participants by arm

ArmCount
Academic Detailing (AD)
Standard of care for patients who are smokers and admitted to the hospital.
477
AD + Integrated Tobacco Order Set
Access to the Integrated Tobacco Order Set (ITOS) Nicotine Replacement Therapy with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center AD + Integrated Tobacco Order Set: Physician will have access to: NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
567
Total1,044

Withdrawals & dropouts

PeriodReasonFG000FG001
12 Month Biochemical VerificationDeath2230
12 Month Biochemical VerificationLost to Follow-up5071
12 Month Biochemical Verificationsubject did not self-report abstinence352401
12 Month Follow-upDeath2230
12 Month Follow-upLost to Follow-up5071
1 Month Follow-upDeath23
1 Month Follow-upLost to Follow-up4138
6 Month Follow-upDeath1313
6 Month Follow-upLost to Follow-up3958

Baseline characteristics

CharacteristicAcademic Detailing (AD)AD + Integrated Tobacco Order SetTotal
Age, Continuous49.3 years
STANDARD_DEVIATION 12.6
49.3 years
STANDARD_DEVIATION 11.7
49.3 years
STANDARD_DEVIATION 12.1
Cigarettes/day10.0 cigarettes per day10.5 cigarettes per day10.0 cigarettes per day
Ethnicity (NIH/OMB)
Hispanic or Latino
51 Participants61 Participants112 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
426 Participants506 Participants932 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Heavy Smoking Index >= 4, N (%)208 Participants210 Participants418 Participants
Race (NIH/OMB)
American Indian or Alaska Native
4 Participants1 Participants5 Participants
Race (NIH/OMB)
Asian
2 Participants3 Participants5 Participants
Race (NIH/OMB)
Black or African American
157 Participants170 Participants327 Participants
Race (NIH/OMB)
More than one race
11 Participants18 Participants29 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants3 Participants3 Participants
Race (NIH/OMB)
White
303 Participants372 Participants675 Participants
Region of Enrollment
United States
477 participants567 participants1044 participants
Sex: Female, Male
Female
238 Participants286 Participants524 Participants
Sex: Female, Male
Male
239 Participants281 Participants520 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 0
other
Total, other adverse events
0 / 00 / 0
serious
Total, serious adverse events
0 / 00 / 0

Outcome results

Primary

Number of Participants With Exhaled Carbon Monoxide Confirmed Abstinence

Tobacco abstinence will be assessed by obtaining an exhaled carbon monoxide reading for all subjects self-reporting tobacco abstinence at 12 month follow-up. Consistent with manufacturer's recommendations, a cutoff of 10 ppm will indicate current smoking.

Time frame: 12 months post enrollment

Population: Only participants self-reporting abstinence during the 12 month follow-up call were asked to provide biochemical verification.

ArmMeasureValue (NUMBER)
Academic Detailing (AD)Number of Participants With Exhaled Carbon Monoxide Confirmed Abstinence53 participants
AD + Integrated Tobacco Order SetNumber of Participants With Exhaled Carbon Monoxide Confirmed Abstinence65 participants
Secondary

Number of Participants Self-Reporting Treatment Engagement - 1 Month

Treatment engagement will be assessed by subject self-report during the 1 month follow-up interview. Subjects will be considered engaged in treatment if at 30 days after randomization the subject reports currently receiving care for the Quitline or another treatment program that addresses the subject's nicotine dependence.

Time frame: 1 month post enrollment

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Academic Detailing (AD)Number of Participants Self-Reporting Treatment Engagement - 1 Month32 Participants
AD + Integrated Tobacco Order SetNumber of Participants Self-Reporting Treatment Engagement - 1 Month80 Participants
Secondary

Number of Participants Self-Reporting Use of Cessation Medications - 12 Months

NRT use and use of other pharmacotherapies will be assessed by self-report. A Treatment Services Review (TSR) will be administered during follow-up assessments at 1, 6, and 12 months post enrollment.

Time frame: 12 months post enrollment

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Academic Detailing (AD)Number of Participants Self-Reporting Use of Cessation Medications - 12 Months100 Participants
AD + Integrated Tobacco Order SetNumber of Participants Self-Reporting Use of Cessation Medications - 12 Months136 Participants
Secondary

Number of Participants Self-Reporting Use of Cessation Medications - 1 Month

Nicotine replacement therapy (NRT) use and use of other pharmacotherapies will be assessed by self-report. A Treatment Services Review (TSR) will be administered during follow-up assessments at 1, 6, and 12 months post enrollment.

Time frame: 1 month post enrollment

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Academic Detailing (AD)Number of Participants Self-Reporting Use of Cessation Medications - 1 Month126 Participants
AD + Integrated Tobacco Order SetNumber of Participants Self-Reporting Use of Cessation Medications - 1 Month187 Participants
Secondary

Number of Participants Self-Reporting Use of Cessation Medications - 6 Months

NRT use and use of other pharmacotherapies will be assessed by self-report. A Treatment Services Review (TSR) will be administered during follow-up assessments at 6 months post enrollment.

Time frame: 6 months post enrollment

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Academic Detailing (AD)Number of Participants Self-Reporting Use of Cessation Medications - 6 Months100 Participants
AD + Integrated Tobacco Order SetNumber of Participants Self-Reporting Use of Cessation Medications - 6 Months146 Participants
Secondary

Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 12 Months

Self-report questionnaires are completed over the phone to assess reduction in cigarette use or abstinence from cigarette use. The Time Line Follow Back technique will be used to assess 7-day point prevalence abstinence.

Time frame: 12 months post enrollment

Population: Only includes participants who completed the 12 month follow-up appointment.

ArmMeasureValue (NUMBER)
Academic Detailing (AD)Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 12 Months78 participants
AD + Integrated Tobacco Order SetNumber of Participants With Self-Reported Tobacco Reduction or Abstinence - 12 Months86 participants
Secondary

Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 1 Month

Self-report questionnaires are completed over the phone to assess reduction in cigarette use or abstinence from cigarette use. The Time Line Follow Back technique will be used to assess 7-day point prevalence abstinence.

Time frame: 1 month post enrollment

Population: Includes only participants who completed 1 month follow-up appointment.

ArmMeasureValue (NUMBER)
Academic Detailing (AD)Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 1 Month72 participants
AD + Integrated Tobacco Order SetNumber of Participants With Self-Reported Tobacco Reduction or Abstinence - 1 Month87 participants
Secondary

Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 6 Months

Self-report questionnaires are completed over the phone to assess reduction in cigarette use or abstinence from cigarette use. The Time Line Follow Back technique will be used to assess 7-day point prevalence abstinence.

Time frame: 6 months post enrollment

Population: Includes only participants who completed the 6 month follow-up appointment.

ArmMeasureValue (NUMBER)
Academic Detailing (AD)Number of Participants With Self-Reported Tobacco Reduction or Abstinence - 6 Months68 participants
AD + Integrated Tobacco Order SetNumber of Participants With Self-Reported Tobacco Reduction or Abstinence - 6 Months83 participants

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026